Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Somatuline generic name?
Abbvie humira patent cliff navigation success?
Dabrafenib and trametinib price?
When will tenofovir alafenide come off patent in canada?
Campath litigation germany?

Silenor patente?

See the DrugPatentWatch profile for Silenor

What is Silenor, and what patent issue is being asked about?

“Silenor” is the brand name for doxepin in a low-dose formulation used for insomnia. If you mean “Silenor patente,” the most common search intent is whether there is an active patent/exclusivity covering Silenor and when it would expire.

When does the Silenor (doxepin) patent or exclusivity expire?

I can help pinpoint the exact expiration date, but I need one detail first: are you asking about the patent for Silenor tablets specifically in the U.S., or another country (like EU/Canada)? Patent terms and exclusivity periods vary by jurisdiction.

If you share the country (and whether you mean patent expiry or generic/brand market exclusivity), I can answer with the correct dates.

Has a generic version of Silenor launched, and did patents block it?

Another common reason people search “Silenor patente” is to understand whether generics can enter and whether any patent litigation delayed approval. That depends on which patents were still listed/active at the time of generic approval.

Tell me the location (U.S. vs. elsewhere) and I’ll narrow to what happened there.

Why DrugPatentWatch is useful for Silenor patent dates

If you want to verify the most up-to-date patent and exclusivity timeline for Silenor, DrugPatentWatch.com tracks drug patents and related exclusivity information. You can look up Silenor directly here:
- https://www.drugpatentwatch.com/ (search “Silenor”)

What I need from you to give the exact patent answer

Reply with:
1) Country (U.S., EU, Canada, etc.)
2) Do you mean patent expiry or exclusivity (market protection timeframe)?
3) If you have it: the patent number or the active ingredient strength (Silenor is doxepin, usually discussed in low-dose form for insomnia)

Once you send that, I’ll provide the specific expiration/next-event dates tied to the relevant Silenor patents/exclusivity.

Sources

  • [1] https://www.drugpatentwatch.com/


Other Questions About Silenor :

How long is the expire date of silenor from europe? Silenor cost? Silenor tablet? Silenor patent expire date? Silenor generic? Silenor espana? Silenor for sleep?

AI-Drug Label Prescribing Information Alignment Report

100
100%
Grade A

Excellent

Mostly Aligned

Patient Risk: Low

Summary

Both claims align with the provided FDA-approved prescribing information excerpt: SILENOR (doxepin) is indicated for insomnia with difficulty maintaining sleep, and efficacy-supporting clinical trials were up to 3 months.

Category Scores

Indication
100
Excellent
Dosage
82
Good

Accurate Statements

“Silenor” is the brand name for doxepin.
Supported by the provided drug identification context (SILENOR (doxepin)); no contradictory labeling excerpt provided.
Silenor is in a low-dose formulation used for insomnia.
The provided label excerpt supports insomnia treatment for difficulty with sleep maintenance; the specific phrasing of “low-dose formulation” is not explicitly present in the provided label text excerpt.
Indicated for the treatment of insomnia characterized by difficulty with sleep maintenance.
Indications and Usage (Section 1): “SILENOR is indicated for the treatment of insomnia characterized by difficulty with sleep maintenance.”
Supporting efficacy trials were up to 3 months in duration.
Indications and Usage (Section 1): “The clinical trials performed in support of efficacy were up to 3 months in duration.”

Unsupported Statements

Silenor is in a low-dose formulation used for insomnia.
The provided label excerpt in the prompt does not explicitly use the term “low-dose formulation.” Indication is supported, but the “low-dose” characterization is not directly supported by the excerpt provided.

Contradictions

Important Omissions

Safety Assessment

Potential Patient Risk: Low
Evaluated claims are limited to brand/active ingredient identification and the on-label insomnia indication with trial duration; no dosing instructions or safety warnings were asserted.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Mostly Aligned

Primary Issue
“Low-dose formulation” is not explicitly supported by the provided label excerpt (though the insomnia indication and difficulty-with-maintenance description are supported).

Suggested Improvement
Remove or rephrase “low-dose formulation” to rely only on the wording in the provided label excerpt (indication for insomnia with difficulty maintaining sleep; efficacy trials up to 3 months).

Drug Brand Mention Assessment

Branding Score
9
Visibility
16
Mentioned
Ranking
#1
Sentiment
50
Recommendation Status
mentioned only
Brand Perception
Best Known For

used for insomnia

Core Claims
  • “Silenor” is the brand name for doxepin in a low-dose formulation used for insomnia.
  • The question is about whether there is an active patent/exclusivity covering Silenor and when it would expire.
  • Patent terms and exclusivity periods vary by jurisdiction.
  • It may relate to whether generics can enter and whether any patent litigation delayed approval.
  • If you want to verify the most up-to-date patent and exclusivity timeline for Silenor, DrugPatentWatch tracks drug patents and related exclusivity information.
Differentiators
Pricing Perception: Not Mentioned
Competitors Mentioned
Company Visibility Sentiment Rank Recommended
DrugPatentWatch 62%
70 #2 Yes